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Involvement of mtDNA Damage Elicited by Oxidative
Stress in the Arsenical Skin Cancers
Chih-Hung Lee1,6, Shi-Bei Wu2,6, Chien-Hui Hong3,4, Gwo-Shin Chen1, Yau-Huei Wei2,5,7 and Hsin-Su Yu1,7
Arsenic causes several human cancers. Arsenic-induced Bowen’s disease (As-BD), the most common arsenical
cancer, is characterized by increased proliferation, dysplasia, and individual cell apoptosis, all of which involve
mitochondria. We reported that arsenic causes aberrant keratinocyte proliferation through mtTFA-mediated
mitochondrial biogenesis in As-BD. Increasing mitochondrial biogenesis causes cells to undergo oxidative
stress. However, how arsenic induces oxidative stress and causes mtDNA damage in arsenical cancers remains
largely unknown. Using tissues from As-BD patients and arsenic-treated keratinocytes, we determined the
oxidative stress, antioxidant enzymes, DNA-repair enzymes, and 8-hydroxy-2’-deoxyguanosine (8-OHdG) level in
mtDNA by immunofluorescence, real-time PCR, and western blot. The results showed that oxidative stress
was enhanced in both As-BD and arsenic-treated keratinocytes. Antioxidant enzymes including manganese-
superoxide anion and copper/zinc-superoxide anion and DNA-repair enzymes were upregulated concomitantly
in tissues and cells. In arsenic-treated keratinocytes, increased mitochondrial oxidative stress and the 8-OHdG
level in mtDNA were attenuated by pretreatment with ascorbic acid, a potent antioxidant. Further, we found
several somatic mutations in the ND4, ND5, and ND6 genes of mtDNA in lesional but not in perilesional skin from
As-BD patients. Taken together, the results suggest that oxidative damage and mutations to mtDNA might be
involved in the arsenical skin cancers in the context of mitochondrial biogenesis.
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INTRODUCTION
Arsenic is the 20th most common element in the earth’s crust.
Arsenic has been designated as a Class I carcinogen by (IARC
(2004)). Long-term exposure to arsenic can cause human
cancers in the skin, lung, bladder, and liver. Among these
cancers, skin cancers are the most common (Yeh, 1973).
The prevalence odds ratio to develop skin cancers increases
proportionally to the concentrations of arsenic in well water in
West Bengal (Haque et al., 2003), Bangladesh (Ahsan et al.,
2006), and Inner Mongolia (Guo et al., 2006). The arsenical
skin cancers include Bowen’s disease (carcinoma in situ),
squamous cell carcinoma, basal cell carcinoma, and mixed
forms (Yeh et al., 1968; Abernathy et al., 1999; Centeno et al.,
2002). Among these skin cancers, Bowen’s disease is the most
common. Arsenic-induced Bowen’s disease (As-BD) tends to
affect multiple sites predominantly distributed in sun-spared
skin, whereas non-As-BD disease (or UV-induced) tends to
affect a solitary site in the sun-exposed skin (Lee et al., 2004).
In addition, in patients with As-BD, there are usually
variegated hyperpigmentations on the back and chest with
characteristic palmar plantar arsenic keratosis (Tseng et al.,
1968). In contrast, the classical Bowen’s disease is mostly
located in sun-exposed skin without such pigmentary
abnormalities and palmar plantar keratosis (Yeh et al.,
1968). Microscopically, As-BD is characterized by increased
proliferation, dysplasia, and occasional apoptosis. Although
similar in histopathology, As-BD and classical UV-induced
Bowen’s disease have distinct pathophysiogical mechanisms
in apoptosis of affected cells (Lee et al., 2004), immune
interactions (Liao et al., 2009), and mitochondrial biogenesis
(Lee et al., 2011; Martinez-Outschoorn et al., 2011). The
carcinogenic mechanism of arsenical skin cancers has not
been fully understood. Arsenic acts as a double-edged sword
in the progression of cancers. At one end, it is the treatment of
choice for acute promyelocytic leukemia (Kamimura et al.,
2011), and at the other end, it causes several kinds of
cancers. Interestingly, at lower doses, arsenic promotes cell
proliferation, but at higher doses, arsenic induces cell death
in various cell types (Yu et al., 1992; Gupta et al., 2003; Liao
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et al., 2004). Mitochondria appear to be a reasonable target in
the process of arsenical carcinogenesis because cell
proliferation (Martinez-Outschoorn et al., 2011), cell death
(Lee and Wei, 2000), and abnormal cell differentiation (Chen
et al., 2010a) all require the participation of mitochondria. In
fact, genetic and metabolic alterations in mitochondria
have been shown to be the cause or contributory factors of
carcinogenesis (Modica-Napolitano and Singh, 2002;
Petros et al., 2005; Ishikawa et al., 2008). Many cancers
are characterized by mitochondrial abnormalities that are
associated with disease progression and patient survival
(Petros et al., 2005; Ishikawa et al., 2008). Mutations and
damage to mtDNA were found in solid tumors as well as in
lymphoma-leukemia (Czarnecka et al., 2010). Oxidative
stress-induced mutation and damage of mtDNA, and
mitochondrial dysfunction are thought to have an important
role in carcinogenesis. This notion was supported by the
findings that mutated cancer-causing proteomic alteration
feedback amplified the cell transformation process by
directly affecting mitochondrial function and promoted a
vicious spiral of malignant cell transformation (Kulawiec
et al., 2006).
The peripheral blood mononuclear cells of patients with
arsenical skin cancers had elevated levels of intracellular
reactive oxygen species (ROS), mitochondrial membrane
permeability, and increased cytochrome-c release, leading to
activation of caspase cascades and apoptosis (Banerjee et al.,
2008). We have previously demonstrated that low doses of
arsenic-induced mtTFA-mediated mitochondrial biogenesis,
resulting in aberrant cell proliferation in arsenical skin
cancers and in arsenic-treated keratinocytes (Lee et al.,
2011). This is supported by a recent study demonstrating
that chronic exposure to arsenic increases cell survival in
human prostate epithelial cells through mtTFA (Singh et al.,
2011). Therefore, we have contended that upregulation
of biogenesis and function of mitochondria are involved in
arsenic carcinogenesis. However, increased mitochondrial
biogenesis and respiratory function might also increase the
chance to develop oxidative stress that can render the mtDNA
more susceptible to oxidative damage and mutation.
Consequently, the sustained mtDNA damage would interfere
with the mitochondrial function leading to the overproduction
of ROS in the mitochondria of arsenic-exposed cells.
Partridge et al. (2007) reported that arsenic can reduce the
mitochondrial biogenesis, cytochrome-c oxidase activity, and
oxygen consumption in Chinese hamster ovary-derived cells .
However, the direct target cells in arsenic carcinogenesis in
the skin are keratinocytes that originate from ectoderm, but
not endoderm, that develops into ovary in embryogenesis.
Further, the Chinese hamster ovary-derived cells are distinct
from primary keratinocytes because they belong to a cell line
and lack EGFR expression that is essential for epidermal
differentiation (Ahsan et al., 2009). The effects of arsenic on
cells appear to be dependent on cell type. We have reported
that low doses of arsenic induce mitochondrial biogenesis,
increase oxygen consumption, and induce cytochrome-c
oxidase function in both As-BD disease and arsenic-treated
primary keratinocytes (Lee et al., 2011). Thus, the role of
oxidative stress and mtDNA damage in the pathogenesis of
arsenical cancers in primary keratinocytes has never been well
addressed. Therefore, this study was aimed to answer
whether arsenic could induce mitochondrial oxidative stress,
leading to oxidative damage and instability of mtDNA in
arsenical cancers in the context of increased mitochondrial
biogenesis. We also examined whether the ROS scavengers
would be altered in response to arsenic-induced mitochon-
drial oxidative stress and subsequent mitochondrial damage.
RESULTS
Increased oxidative stress and oxidative DNA damage in
arsenical skin cancers
To study whether oxidative damage is present in arsenical
cancers, we measured the contents of 8-hydroxy-2’-deoxy-
guanosine (8-OHdG) in DNA of skin tissues from As-BD,
non-As-BD patients, and age-matched normal controls by
immunofluorescence staining. The results showed that the
8-OHdG level in skin DNA was increased in As-BD patients
as compared with those in normal subjects and non-As-BD
patients, respectively (Figure 1a). We also investigated
whether the expression levels of antioxidant enzymes were
elevated to accommodate the increased oxidative stress in
As-BD. We determined and compared the expression levels of
copper/zinc-superoxide anion (Cu/Zn-SOD), manganese-
superoxide anion (Mn-SOD), and catalase in skin tissues
of As-BD patients, non-As-BD patients, and normal subjects
by immunofluorescence. The results showed that the expres-
sion levels of Cu/Zn-SOD and Mn-SOD were increased
(Figure 1b and c), whereas the expression of catalase was
slightly reduced in skin tissues from As-BD patients compared
with those from non-As-BD patients or normal subjects
(Figure 1d). These findings indicate that the oxidative stress
level was increased, accompanied with an imbalanced
expression of antioxidant enzymes, which may account for
the increased oxidative DNA damage in As-BD.
Increased expression of antioxidant enzymes and DNA-repair
enzymes in arsenical skin cancers
We then investigated whether the above finding of the altered
expression of antioxidant enzymes could be observed at
the transcriptional level in skin tissues of As-BD patients.
The expression levels of DNA repair-related enzymes in skin
tissues of As-BD patients were also investigated. To achieve
this goal, we profiled the expression levels of anti-
oxidant enzymes and DNA-repair enzymes by real-time
quantitative PCR (RT-QPCR) in lesional and perilesional skin
tissues from As-BD patients. Among the six antioxidant
enzymes or proteins examined (Cu/Zn-SOD, Mn-SOD,
catalase, glutathione peroxidase-1, thioredoxin-1, and per-
oxiredoxin-1), except a slight reduction in catalase, all of
the other five antioxidant enzymes were upregulated in
lesional skin tissues compared with those in perilesional
skin tissues of As-BD patients (Figure 2a). Moreover, all of the
five DNA-repair enzymes (hOGG1, p53, XPC, ERCC1, and
GADD45) were significantly upregulated in lesional skin
tissues compared with those in perilesional skin tissues of
As-BD patients (Figure 2b). These findings indicate that the
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expression levels of antioxidant enzymes and DNA-repair
enzymes were altered in the cancerous tissues but not in the
perilesional skin from the As-BD patients, suggesting a cellular
defense against oxidative stress in the arsenical skin cancers.
Alterations in the expression of antioxidant enzymes and
DNA-repair enzymes in arsenic-treated human keratinocytes
To investigate whether the oxidative stress, oxidative damage,
altered expression of antioxidant enzymes, and DNA-repair
enzymes observed in skin tissues of As-BD patients could
be reproduced in vitro, we treated human keratinocytes with
arsenic (0, 0.5, 1, or 5mM) for 24 hours and measured the
expressions of the above antioxidant enzymes and DNA-
repair enzymes by RT-QPCR. There was a dose-dependent
increase in the mRNA levels of both families of enzymes in
arsenic-treated keratinocytes (Figure 3a and b). The expression
level of Mn-SOD was most significantly increased among
the antioxidant enzymes in skin tissues of As-BD patients
and increased in arsenic-treated keratinocytes in a dose-
dependent manner (Figure 3a). However, the expression of
catalase was dramatically decreased in keratinocytes treated
with a high concentration (5mM) of arsenic. The results
from arsenic-treated keratinocyte were consistent with those
observed ex vivo, which revealed a cellular defense against
oxidative stress. Furthermore, we measured the protein
expression of antioxidant enzymes in arsenic-treated keratino-
cytes by western blot. The results revealed a dose-dependent
increase of the expression of antioxidant enzymes in
Normal control skin Normal control skin
Normal control skin
Non-As-BD Non-As-BD
Non-As-BD
Isotype Isotype
Isotype
Non-As-BD
Isotype
As-BD As-BD
As-BD
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As-BD
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SOD-1
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Catalase
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DAPI and 8-OHdG DAPI and Cu/Zn-SOD (SOD-1)
DAPI and Mn-SOD(SOD-2) DAPI and catalase
SOD-2
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Figure 1. Increased levels of oxidative DNA damage and altered expression of antioxidant enzymes in arsenical skin cancers. (a) Skin tissues from normal
subjects, patients with arsenic-induced Bowen’s disease (As-BD) and non-As-BD (n¼ 6 for each group), respectively, were processed for immunofluorescence
staining to measure the levels of 8-hydroxy-2’-deoxyguanosine (8-OHdG) in DNA (red) and 4’,6-diamidino-2-phenylindole (DAPI) intensity (blue).
Isotype IgG antibodies were included as negative controls for determination of the 8-OHdG level using a mAb against 8-OHdG. (b) Skin tissues from normal
subjects, As-BD patients, and non-As-BD patients (n¼ 6 for each group), respectively, were processed for immunofluorescence intensity measurement of the
expression of copper/zinc-superoxide anion (Cu/Zn-SOD) (red), (c) the expression of manganese-superoxide anion (Mn-SOD) (green), and (d) the expression of
catalase (green) and DAPI intensity (blue). Matched isotype IgG antibodies against Cu/Zn-SOD, Mn-SOD, and catalase, respectively, were included as negative
controls. Bar ¼ 30mM.
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arsenic-treated keratinocytes (Figure 3c and d). Again, an
exception of the dose-dependent phenomenon was found in
the expression of catalase, which peaked in kerationcytes
treated with 0.1–1mM arsenic while returning to baseline in
keratinocytes treated with 5mM arsenic. These findings suggest
that arsenic-induced increase of oxidative stress and altered
expression of antioxidant enzymes could be reproduced
in vitro, and keratinocytes can be used in the subsequent
mechanistic studies.
Enhanced mtDNA damage by oxidative stress in skin of
As-BD patients and in arsenic-treated keratinocytes
We reported that mitochondrial biogenesis was enhanced in
arsenical skin cancers and in arsenic-treated keratinocytes
(Lee et al., 2011). Because we found a general increase
in oxidative stress and inductions of the antioxidant
enzymes, we then investigated whether mitochondria,
a major source of oxidative stress in human cells, are
vulnerable to oxidative damage while undergoing substantial
mitochondrial biogenesis. To address this, we measured the
oxidative damage to mtDNA in As-BD and in arsenic-treated
keratinocytes, respectively. The results revealed that the level
of oxidative damage to mtDNA was significantly increased in
lesional skin as compared with the perilesional skin from
As-BD patients (Figure 4a). Furthermore, there was a dose-
dependent increase of mtDNA damage in arsenic-treated
keratinocytes (Figure 4b). The induction of mtDNA damage
in vitro could be abolished when keratinocytes had been
treated for 4 hours with 100mM ascorbic acid, a potent
antioxidant (Figure 4b). These findings indicate that mito-
chondrial oxidative stress may mediate oxidative damage to
mtDNA in arsenical skin cancers.
Somatic mutations of mitochondrial genome in the lesional
skin from As-BD patients
We found increased oxidative mtDNA damages in the lesional
skin from As-BD patients. We then asked whether there were
mtDNA mutations consistent with oxidative damage in tissues
of patients with As-BD. The entire mitochondrial genome
was directly sequenced to identify the somatic mutations in
the lesional As-BD skin as compared with that in perilesional
skin tissues to further contend that mtDNA mutation-elicited
oxidative stress involved in the carcinogenesis of arsenical
skin cancers. The result showed that five somatic mutations in
the mitochondrial genome occurred in for out of six As-BD
patients (Figure 2 and Supplementary Figure 1 online). Table 1
summarizes these somatic mutations of mtDNA were
identified from As-BD patients. Of these, A14230G,
T11076A, C12405, and T14783C are homoplasmic mutations,
and A11035T is a heteroplasmic mutation of mtDNA. The
A14230G, T11076A, C12405, and A110357T mutations are
located in the ND4, ND5, and ND6 genes that encode the key
components of mitochondrial Complex I. The T14783C
mutation is on the Cyt b gene, one of the essential components
of mitochondrial Complex III. Except for C12405 and
T14783C mutations being synonymous, other mutations can
cause a substitution of amino acid (A14230G, A11035T) or
premature termination (T11076A). The result showed that the
somatic mutations of mtDNA are present in two-thirds of
the As-BD lesion. These mutations can occur in the genes
encoding the major component of mitochondrial respiratory
enzyme Complex I and they are different from the large-scale
deletions of mtDNA that are commonly induced by UV
irradiation (Krishnan et al., 2004; Eshaghian et al., 2006).
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Figure 2. Increased expression of antioxidant enzymes and DNA-repair
enzymes in the lesional skin tissues of arsenic-induced Bowen’s disease
(As-BD) patients. Lesional parts and perilesional parts of skin tissues of As-BD
patients (n¼ 6 for the pair skin specimens) were processed for TaqMan-based
real-time quantitative PCR (RT-QPCR) to evaluate and compare the expression
levels of (a) antioxidant enzymes and (b) DNA-repair enzymes. The expression
level of each gene of interest was normalized with the corresponding
expression of b-actin, and the average was calculated from the results obtained
with perilesional and lesional parts of skin tissues of six As-BD patients,
respectively. Data were assessed in triplicate and expressed as means±SD.
(*,#Po0.05; **Po0.01 vs. the indicated group; *and **indicate an increase;
#indicates a decrease). Cu/Zn-SOD, copper/zinc-superoxide anion;
ERCC1, excision repair cross complementation 1; GADD45, growth arrest and
DNA-damage-inducible protein 45; GPx-1, glutathione peroxidase-1; hOOG1,
human 8-oxoguanine DNA N-glycosylase 1; Mn-SOD, manganese-superoxide
anion; Prx, peroxiredoxin-1; p53, tumor protein 53; Trx-1, thioredoxin-1;
XPC, xeroderma pigmentosum complementation group C.
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Mitochondria-elicited oxidative stress may enhance mtDNA
damage in arsenical skin cancers
Because we have found an increase of oxidative stress,
oxidative mtDNA damage, and mtDNA mutations in the skin
tissues of As-BD patients and in arsenic-treated kerationcytes,
we then examined whether oxidative stress is increased in
mitochondria of the affected cells. If so, would antioxidants
attenuate the mitochondrial oxidative stress that contributed to
mtDNA damage? To address this, we treated keratinocytes
with arsenic at 0, 0.1, and 1mM for 72 hours, and measured
the oxidative stress by staining the cells with MitoSOX, a
sensitive indicator for mitochondrial ROS. We then pretreated
keratinocytes with ascorbic acid, a potent ROS scavenger
for 4 hours before treatment of keratinocytes with arsenic for
72 hours. The results showed that the fluorescence of
MitoSOX was apparent in keratinocytes treated with either
0.1 or 1mM of arsenic (Figure 5a–c). The increase in mitochon-
drial oxidative stress by arsenic could be blocked when
keratinocytes had been pretreated with 100mM ascorbic
acid for 4 hours (Figures 5d–f), suggesting that arsenic induced
the increase of mitochondrial oxidative stress as a result of
imbalance between oxidative and reducing events.
DISCUSSION
In this study, we demonstrated that the arsenic-elicited
mitochondrial oxidative stress with compensatory antioxidant
responses is accompanied by the accumulation of oxidative
damage and mutation of mtDNA in arsenical cancers. Mito-
chondria seem to be a reasonable target in the process
of arsenical carcinogenesis because pathological features of
As-BD, including cell proliferation, cell death, and dysplasia
all require the participation of mitochondria. Our findings
support the notion that oxidative stress-elicited mtDNA
damage and mutation contribute to arsenical carcinogenesis
and treatment of keratinocytes with antioxidants such
as ascorbic acid could ameliorate the arsenic-induced
mitochondrial oxidative stress and oxidative damage to
mtDNA (Figure 5g).
Oxidative damage and instability of mtDNA occur concur-
rently with increased ROS in several cancers (Ralph et al.,
2010). The majority of previous studies investigated the role
that ROS has in carcinogenesis with regard to their pro-
apoptotic effects. However, how ROS get involved in
oxidative damage and mutation of mtDNA in arsenic
carcinogenesis remains unknown. ROS are able to induce
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Figure 3. Arsenic induced dose-dependent alterations in the expression of antioxidant enzymes and DNA-repair enzymes in human primary keratinocytes.
Human primary cultures of skin keratinocytes were treated for 24 hours with arsenic at 0, 0.1, 1, and 5mM, respectively. (a) The gene expression levels of
antioxidant enzymes and (b) DNA-repair enzymes were measured by TaqMan-based real-time quantitative PCR (RT-QPCR). (c) The protein expression levels of
antioxidant enzymes, including manganese-superoxide anion (Mn-SOD), copper/zinc-superoxide anion (Cu/Zn-SOD), catalase, glutathione peroxidase-1 (GPX-1),
thioredoxin-1 (TRx-1), and peroxiredoxin-1 (Prx-1), were measured by western blot. (d) By densitometric analysis from three independent western blots, the
expression levels of proteins of interest in As-treated keratinocytes were quantified and normalized by the expression level of b-actin. Data are presented as
means±SD. (*Po0.05; **Po0.01 vs. the indicated group).
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oxidative damage to DNA, RNA, and proteins, and thereby
render cells susceptible to mutagenesis and carcinogenesis.
The mitogenic potential of ROS was revealed by the
observation that ROS stimulated cell proliferation of
hepatoma via the cross-talk between PI3K and JNK
pathways, which in turn enhance protein expression of c-Fos
and c-Jun (Liu et al., 2002). Meanwhile, mitochondria are the
main source of ROS in human cells (Berneburg et al., 2006). It
was reported that oxidative damage to nuclear DNA were
increased in HeLa cells with defective mitochondria and
mtDNA-depleted r0 cells (Delsite et al., 2003). A study using
Caenorhabditis elegans showed that mitochondrial oxi-
dative stress results in nuclear hypermutability (Hartman
et al., 2004). Furthermore, mitochondrial genome instability
and mitochondrial ROS could enhance the intestinal
tumorigenesis in a mouse adenomatous polyp model (Woo
et al., 2012). Based on this study, we contend that the
accumulation of oxidative damage in mtDNA by arsenic-
elicited mitochondrial ROS production may lead to a
‘‘vicious cycle’’, which in turn affects the instability of the
mitochondrial genome and causes the mutation of mtDNA,
subsequently generating more mitochondrial ROS through
impaired respiratory function of mitochondria (Figure 5g).
Our results suggest that arsenic increases mitochondrial oxida-
tive stress, potentiating mtDNA damage and mutation, which
might drive the carcinogenic progression in arsenical cancers.
Arsenic causes oxidative stress in several types of cancer
cells, mostly at concentrations higher than 5mM. The majority
of arsenic-induced ROS is generated from mitochondria,
as revealed by the observation that Complex I inhibitor
completely abrogated the increase of ROS induced by arsenite
in murine keratinocytes (Corsini et al., 1999). We showed
previously that mitochondrial biogenesis is critical in
promoting aberrant proliferation of arsenic-treated human
primary keratinocytes (Lee et al., 2011). The expression
of factors regulating mitochondrial biogenesis, including
PGC-1a, NRF-1, and mtTFA, are increased in arsenic-treated
human primary keratinocytes. It was reported that the
upregulation of PGC-1a not only increases mitochondrial
biogenesis but also enhances the antioxidant defense system
in vascular endothelial cells to coping with oxidative stress
(Valle et al., 2005). We showed that arsenic-induced stress
response in affected cells includes not only the increase
of mitochondrial biogenesis but also an upregulation of
antioxidant enzymes and DNA-repair enzymes in primary
keratinocytes and in arsenical skin cancers. Most importantly,
in the lesional skin tissues of patients with arsenical cancers,
we found five point mutations of mtDNA, which are located
on the ND4, ND5, ND6, and Cyt b genes. Because these
somatic mutations are located on the coding region of
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Figure 4. Increased mtDNA damage in tissues of As-BD patients
and in cultured keratinocytes. (a) Lesional parts and perilesional parts
of skin tissues from As-BD patients (n¼ 6, BD1-BD6) were processed
for real-time quantitative PCR (RT-QPCR) according to methods described to
estimate the DCt, an indicator for mtDNA oxidative damage. The DCt is the
difference between Ct-T (Ct value from DNA sample treated with human
8-oxoguanine DNA glycosylase (hOGG1)) and Ct-N (Ct value from DNA
sample without hOGG1 treatment). The larger the DCt is, the more
8-hydroxy-2’-deoxyguanosine (8-OHdG) the sample contains. (b) Human
primary keratinocytes were treated with arsenic at 0, 0.1, 1, and 5mM
for 24 hours with or without pretreatment of cells with 100mM ascorbic
acid (Vit C) for 4 hours. The DCt values were measured and calculated
by RT-QPCR. Data are presented as means±SD of the results from
three independent experiments. (*Po0.05; **Po0.01 vs. the indicated
group).
Table 1. Summary of somatic mtDNA mutation in the
paired lesional and perilesional skin tissues from As-BD
patients
Patient
code
Alteration in the coding region of the
indicated mtDNA mutation
n.p. Mutation Gene Amino-acid change
BD1 14230 A-G ND6 Tyr (ATA)-Val (GTA)
BD2 14230 A-G ND6 Tyr (ATA)-Val (GTA)
BD4 11076 T-A ND4 Leu (TTA)-stop codon
(TAA)
11035 A-T ND4 Lys (AAA)-Asn (AAT)
BD6 12405 C-T ND5 Leu (CTC)-Leu (CTT)
14783 T-C Cyt b Leu (TTA)-Leu (CTA)
Abbreviations: Asn, asparagine; BD1–BD4, four patients with Bowen’s
disease; Leu, leucine; n.p., nucleotide position; Tyr, tyrosine; Val, valine.
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mtDNA, an error-prone translation and transcription would
occur and cause impairment in OXPHOS in arsenical skin
cancers. Keratinocytes, the targets of arsenic carcinogenesis,
are vulnerable to oxidative stress that is tightly regulated by the
respiratory function and integrity of mitochondria. In fact,
oxidative damage to mtDNA can mediate genotoxicity of
arsenic in CHO cells as revealed by cybrid studies (Liu et al.,
2005). Arsenic can induce mitochondrial dysfunction through
generation of reactive oxygen and nitrogen species, including
superoxide anions and nitrogen oxide (Beckman and Ames,
1996; Flora, 2011).
In this study, we showed an increase of antioxidant
enzymes in arsenic-treated keratinocytes in a dose-dependent
manner. The increase of antioxidant enzymes seems to
be an adaptive response to increased intracellular and mito-
chondrial oxidative stresses. Although the in vitro experiments
took place in a short period of time, the observed increase
of ROS and antioxidant enzymes in arsenical cancers, but not
in non-arsenical cancers, supports the notion that ROS has,
at least in part, a role in the initiation and progression of
arsenic carcinogenesis. A microarray analysis from arsenic-
treated keratinocytes also demonstrated that many genes
involved in antioxidant responses, including glutathione-
related proteins (GCLC, GCLM, and SLC7A11), thioredoxin
(TXNRD1), and the NADPH-dependent protein (PGD), were
upregulated (Bailey et al., 2010). Recent studies also
showed that selective knockdown of antioxidant enzymes
significantly sensitized keratinocytes to arsenic cytotoxicity
(Zhao et al., 2012).
We noted a disparity in the expression of antioxidant
enzymes, resulting from an increased expression of Mn-SOD
and Cu/Zn-SOD, but a decreased expression of catalase,
in arsenical cancers (Figures 2 and 3). This disparity is not
uncommon and is consistent with the study performed in
mouse epithelial cells, which showed that Cu/Zn-SOD-stable
transfectants were sensitive to oxidative chromosomal aberra-
tions and DNA damage, whereas catalase-stable transfectants
corrected or overcorrected the hypersensitivity of the SOD
clones depending on the ratio between the activities of
catalase and SOD (Cerutti et al., 1994).
Although the number of the samples assayed ex vivo
was limited in this study, we obtained a consistent and
reproducible trend by using assays to assess the biological
effects of arsenic on the tissues and cultured cells of patients
with arsenical cancers. The other limitation is the lack of
long-term treatment of keratinocytes by even lower
concentrations of arsenic (for example, for several weeks). An
animal study might be useful to further address the long-term
effects of arsenic in vivo. However, using animal models to
evaluate health effects of arsenic on the human requires
careful interpretation, because a number of differences
in arsenic metabolism and toxicodynamics between the
human and animals have been described (Cohen et al.,
2006). Nevertheless, our current findings provide impor-
tant information about the involvement of mitochondrial
oxidative stress, oxidative damage, and mutation of mtDNA
in arsenical skin cancers. Treatment of patients with
antioxidants to reduce mitochondrial ROS would be a good
therapeutic approach to block the progression of arsenical
cancers.
We conclude that arsenic increases mitochondrial
oxidative stress, which contributes to increased oxidative
damage and mutations to mtDNA in keratinocytes and in
tumor tissues of patients with arsenical skin cancers. These
results suggest that arsenic may cause a ‘‘vicious cycle’’ of
mitochondrial oxidative stress triggered by increased damage
and mutation of mtDNA. Together with enhanced mitochon-
drial biogenesis in As-BD, the above-mentioned findings led
us to conjecture that oxidative damage to mitochondria
may drive the carcinogenic progression in arsenical cancers.
This study also highlights the possible targets to alleviate
mitochondrial oxidative stress and mtDNA damage in arseni-
cal cancers.
MATERIALS AND METHODS
Selection of patients
A total of six patients with Bowen’s disease (As-BD patients,
aged 73.2±8.4 years) from endemic areas were recruited from
southwestern Taiwan, where artesian water was contaminated by
high concentrations of arsenic. All of them had characteristic
variegated pigmentations, palmoplantar keratosis, and multiple kera-
totic lesions. The specimens for the control group were obtained from
the non-sun-exposed skin of six age-comparable normal subjects
(aged 68.3±10.2 years), who did not live in the endemic areas and
did not have a previous history of cancers. Another control group
came from patients with Bowen’s disease without a history of arsenic
poisoning (non-As-BD patients, with an age of 65.3±12.1 years
(n¼ 6)). Skin tissues were collected for immunohistochemistry and
extraction of RNA and DNA. Written informed consent was obtained
from all participants. The study protocol was approved by the
Institutional Review Board of the Kaohsiung Medical University
Hospital and was adhered to the Declaration of Helsinki.
Figure 5. Ascorbic acid blocked the mitochondrial oxidative stress induced by arsenic in human keratinocytes. Human keratinocytes were treated for 24 hours
with arsenic at 0, 0.1, and 1mM with (a–c) or without (d–f) 100mM ascorbic acid (Vit C) pretreatment for 4 hours, respectively. Mitochondrial distribution and the
level of mitochondrial oxidative stress were measured by staining with MitoTracker (green) and MitoSox (red), respectively. Cell nuclei were counterstained by
4’,6-diamidino-2-phenylindole (DAPI) (blue). Three repeated experiments with consistent results were obtained and representative results are shown. (g) A
proposed scheme showing how arsenic-induced mitochondrial reactive oxygen species (ROS) and oxidative damage and mutation of mtDNA contribute to arsenic
carcinogenesis. Besides enhancing mitochondrial biogenesis by the increased mtTFA expression (i), arsenic interferes with the mitochondrial functions
by inducing oxidative damage and mutation of mtDNA through increased ROS production from the impaired mitochondrial respiration. Meanwhile, the cellular
defense system, including antioxidant enzymes (ii) and DNA-repair enzymes (iii) such as manganese-superoxide anion (Mn-SOD) and human 8-oxoguanine
DNA glycosylase (hOGG1), respectively, are upregulated to cope with the arsenic-induced oxidative stress in mitochondria. Of note, antioxidants such as ascorbic
acid (vitamin C) protect keratinocytes from arsenic-induced mitochondrial oxidative stress and oxidative damage to mtDNA.
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Chemicals and antibodies
The monoclonal antibodies against Mn-SOD, Cu/Zn-SOD, catalase,
and 8-OHdG, respectively, were acquired from Abcam (Cambridge,
MA) for immunohistochemical staining. The antibodies against
Mn-SOD and Cu/Zn-SOD were purchased from Stressgen
(Ann Arbor, MI). The antibodies against glutathione peroxidase-1,
glutathione reductase, thioredoxin-1, and peroxiredoxin-1, respec-
tively, were purchased from AbFrontier (Seoul, Korea). The mAb
against b-actin was purchased from Millipore (Billerica, MA). Arsenic
trioxide (As2O3) and ascorbic acid (vitamin C) were obtained from
Sigma-Aldrich Chemical (St. Louis, MO). The fluorescent dyes
of MitoSOX, Mitotracker, and 4’,6-diamidino-2-phenylindole were
acquired from Molecular Probes (Eugene, OR).
Immunohistochemical staining
Sections (5mM) of formalin-fixed, paraffin-embedded tissues were
subjected to immunofluorescence staining according to our previous
protocol (Lee et al., 2011). Sections were stained with primary anti-
bodies against Mn-SOD and Cu/Zn-SOD, catalase, and 8-OHdG
(1:500). The stained specimens were mounted and observed under a
confocal laser scanning microscope (LSM Fluoview 500; Olympus,
Shinjuku, Tokyo, Japan). Image analysis was performed by NIH imageJ
with a native plugin of "region of interest manager". The intensity value
in each region of interest was generated by pseudocolor with gray-
scale transformation (0–255). Mean fluorescence intensity index
(0–255) was averaged from five random high-power fields (or region
of interest).
Keratinocyte primary culture
Normal human keratinocytes were obtained from adult foreskins
through routine circumcision. The keratinocytes were cultured as
described previously (Lee et al., 2004). Keratinocytes at the third
passage were then grown in a keratinocyte serum-free medium
without BPE and rhEGF for 24 hours before experiments.
Analysis of gene expression of antioxidant enzymes and
DNA-repair enzymes
The level of gene expression was determined by TaqMan-based RT-
QPCR as described previously (Lee et al., 2011). Briefly, total RNA
from skin biopsies and cell lysates were extracted with chloroform
after adding the TRIZol reagent (Sigma-Aldrich Chemical), and then
precipitated with isopropanol followed by dissolution of the
RNA in diethylpyrocarbonate-H2O. An aliquot of 5mg RNA was
reverse transcribed to cDNA with a Ready-to-Go RT-PCR kit
(Amersham Biosciences, Uppsala, Sweden) at 42 1C for at least
16 hours. RT-QPCR was performed using the LightCycler TaqMan
probe-based Master kit (Roche Applied Science, Penzberg, Germany)
according to the manufacturer’s instructions. The primer pairs and the
probes used in this study were designed by Universal ProbeLibrary
Assay Design Center (Roche Applied Science) and are listed in
Table 2. The expression levels of the genes of interest were normal-
ized with the expression level of b-actin gene.
Protein extraction and western blotting
Proteins were extracted from cultured keratinocytes, and western
blotting was conducted as described previously (Lee et al., 2006).
Antibodies against target proteins were used at a dilution of 1:500.
Specific proteins in the nitrocellulouse membranes were visualized
using a chemiluminescence subtraction kit (Pierce Chemicals,
Rockford, IL).
Quantitative determination of mtDNA damage
8-OHdG is one of the major ROS-induced base-modified DNA
products, which has been widely accepted as a sensitive marker of
oxidative DNA damage. The content of 8-OHdG in mtDNA was
determined by a RT-QPCR-based technique as described previously
(Chen et al., 2010b). The degree of oxidative damage to mtDNA is
reflected by the abundance of 8-OHdG in mtDNA. If 8-OHdG is
present at a specific region of the DNA, digestion of the 8-OHdG with
Table 2. Oligonucleotide sequences of primers and
TaqMan probes used in this study
Gene
name Primer sequence
Probe
number
mtF3212 FW: 50-ACCATTTGCAGACGCCATAA-30 1
mtR3319 RE: 50-TGAAATTGTTTGGGCTA CGG-30
b-actin FW: 50-ATTGGCAATGAGCGGTTC-30 11
RE: 50-GGATGCCACAGGACTCCAT-30
Mn-SOD FW: 50-TCCACTGCAAGGAACAACAG-30 3
RE: 50-CTGTTGTTCCTTGCAGTGGA-30
Cu/
Zn-SOD
FW: 50-ATGATCTCATTGGATCTTCACG-30 1
RE: 50-CTCCTGAAAAGAGAGCTGCAC-30
Catalase FW: 50-CTCCGGAACAACAGCCTTC-30 89
RE: 50-GAAGGCTGTTGTTCCGGAG-30
GPx-1 FW: 50-TTCCCGTGCAACCAGTTT-30 2
RE: 50-AGGGAATTCAGAATCTCTTCGTT-30
Trx-1 FW: 50-TTAATGGTGGCTTCAAGCTTTT-30 50
RE: 50-AAGTCAAATGCACGCCAAC-30
Prx FW: 50-CAGGCTTGATGGTATCACTGC-30 60
RE: 50-AGGCCTTCCAGTTCACTGAC-30
hOGG1 FW: 50-CTGGCACCCTACCACGTC-30 48
RE: 50-GACGTGGTAGGGTGCCAG-30
p53 FW: 50-CTGGGACGGAACAGCTTTGA-30 12
RE: 50-CCTTTCTTGCGGAGATTCTCTTC-30
ERCC1 FW: 50-GAAATTTGTGATACCCCTCGAC-30 79
RE: 50-GATCGGAATAAGGGCTTGG-30
GADD45 FW: 50-GTGCTTCTACTAAATGCAGGTATTGT-30 17
RE: 50-GCAAGGACTTCATCAGTTTGG-30
XPC FW: 50-GACAAGAGAAAGAAGTGAAAAGATAAAACG-30 2
RE: 50- TGGACCCCTTTATTGAAACGTT-30
Abbreviations: Cu/Zn-SOD, copper/zinc-superoxide anion; ERCC1,
excision repair cross complementation 1; GADD45, growth arrest and
DNA-damage-inducible protein 45; GPx-1, glutathione peroxidase-1;
hOOG1, human 8-oxoguanine DNA N-glycosylase 1; Mn-SOD, manga-
nese-superoxide anion; Prx, peroxiredoxin-1; p53, tumor protein 53; Trx-1,
thioredoxin-1; XPC, xeroderma pigmentosum complementation group C.
1No probes used for SYBR green reactions in quantitative PCR. Probe
numbers indicate the probes of the Universal Probe Set for Human in the
LightCycler TaqMan Master kit (Roche Applied Science) used in this study.
2Specific probe (Fam-50-TCATCGCCCTCCGAAGATATGTCTCAA-
Tamra-30) was purchased from Applied Biosystems.
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human 8-oxoguanine DNA glycosylase (hOGG1; R&D Systems,
Minneapolis, MN) can break the DNA template at the lesion site to
form an abasic site, and thus dramatically reduce the amplification
of this region using PCR. The hOGG1 treatment of DNA samples was
done as previously described (Eshaghian et al., 2006). A volume of
1ml of each DNA was treated with or without 1 U of hOGG1 at 37 1C
for 1 hour, and the digested DNA was amplified by PCR using
mtF3212 and mtR3319 primers (listed in Table 2). The PCR condition
was set as follows: hot start at 95 1C for 10 minutes, followed by
45 cycles of 95 1C for 20 seconds, 62 1C for 20 seconds, and 72 1C for
20 seconds. The fluorescence intensity was measured at the end of
every extension phase at 79 1C. The degree of oxidative mtDNA
damage is defined as DCt, which is the difference between Ct-T (Ct
value from DNA sample treated with hOGG1) and Ct-N (Ct value
from DNA sample without hOGG1 treatment). The larger the DCt is,
the more 8-OHdG the sample contains.
Analysis of the somatic mutations in mtDNA
MtDNA sequence was determined by direct sequencing of the PCR
products amplified with the specific 11 pairs of primers to cover the
entire mitochondrial genome as previously described (Tseng et al.,
2011). PCR was performed for 36 cycles in 40ml of reaction mixture
containing 100 ng DNA, 200mM of each dNTP, 200 pmol of each
primer, 1.25U of high-fidelity PCR enzyme mix (Fermentas Life
Science, St. Leon-Rot, Germany), and 1 high-fidelity PCR buffer
with 1.5 mM MgCl2. The PCR cycles consisted of denaturation process
at 94 1C for 20 seconds, annealing process at 58 1C for 20 seconds,
and extension process at 72 1C for 2 minutes, and after the last cycle,
samples were incubated at 72 1C for 10 minutes to fill-in the
protruding ends of the PCR products. The PCR products were then
sequenced by an ABI BigDye Terminator (version 3.1) cycle
sequencing ready reaction kit and an ABI PRISM 3100 sequencer
(Applied Biosystems, Foster City, CA) according to the manufacturer’s
instructions. We directly compared the paired mtDNA sequences
from lesional and perilesional skin tissues in patients with As-BD.
Any DNA sequence that differed between the two was considered a
somatic mutation.
Statistical analysis
Statistical analysis was performed by using the SigmaPlot, version
12.0 (SPSS, Chicago, IL); and the Microsoft Excel 2010 (Microsoft,
Redmond, WA). The data are presented as means±SD of the results
obtained from three independent experiments. The significance level
of the difference between the control and the experimental groups
was determined by the Student’s t-test, and the difference was
considered significant when P-value was o0.05.
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